FDA clears Eko Murmur Analysis Software (EMAS) for characterising heart murmurs. Credit: Eko Devices Inc.

Digital health company Eko has received US Food and Drug Administration (FDA) clearance for its Cloud-based machine learning algorithm Eko Murmur Analysis Software (EMAS).

The software characterises heart murmurs by assessing heart sounds, phonocardiogram and ECG signals (when available) captured using Eko’s smart stethoscopes.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This characterisation would help healthcare professionals identify structural heart murmurs, which are indicative of valvular heart disease.

According to the company, the use of the EMAS algorithm enables healthcare professionals to identify valvular heart disease with an overall sensitivity of 85.6% and specificity of 84.4%.

The figures further improve to 90.2% and specificity of 90.6% for adults 18 years and older.

See Also:

In comparison, general practitioners (GPs) demonstrated a sensitivity of 44% and specificity of 69% for detecting significant valvular heart disease using traditional stethoscopes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Eko co-founder and CEO Connor Landgraf said: “This latest FDA clearance is another way in which Eko is improving access to better heart health through clinically-validated algorithms and best-in-class medical devices.

“By making heart disease screening algorithms and digital stethoscopes accessible in exam rooms around the country, we are moving towards a future in which more objective and consistent valvular heart disease screening can become the standard of care.”

Around 2.5% of the US population suffers from valvular heart disease, according to data from the Centers for Disease Control and Prevention (CDC).

Eko expects the use of murmur analysis artificial intelligence (AI) and digital stethoscopes to reduce the time taken to detect significant structural heart disease on the front lines of care to just seconds.